<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05126030</url>
  </required_header>
  <id_info>
    <org_study_id>2101</org_study_id>
    <nct_id>NCT05126030</nct_id>
  </id_info>
  <brief_title>TRiCares Topaz Transfemoral Tricuspid Heart Valve Replacement System First In Human Trial</brief_title>
  <acronym>TRICURE</acronym>
  <official_title>TRiCares Topaz Transfemoral Tricuspid Heart Valve Replacement System First In Human Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TRiCares GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TRiCares GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this first in human study is to gain early clinical insight into the safety&#xD;
      profile and performance of the Topaz transcatheter tricuspid valve replacement (TTVR) system&#xD;
      intended for transfemoral access to deliver a self-expanding bioprosthetic valve within the&#xD;
      tricuspid valve.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The TRiCares Topaz Prosthesis is intended to replace a diseased tricuspid heart valve via a&#xD;
      transcatheter approach without removing the native valve.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 15, 2022</start_date>
  <completion_date type="Anticipated">December 15, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Topaz TTVR System</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hierarchical composite endpoint</measure>
    <time_frame>30 days</time_frame>
    <description>including all-cause mortality, re-hospitalization for heart failure, re-intervention for failed tricuspid intervention, and KCCQ worsening at 30 days</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Tricuspid Regurgitation</condition>
  <arm_group>
    <arm_group_label>Primary Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device: Topaz TTVR system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Topaz TTVR System</intervention_name>
    <description>Transcatheter tricuspid heart valve replacement</description>
    <arm_group_label>Primary Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject of age &gt;18 years.&#xD;
&#xD;
          -  Subject with severe symptomatic tricuspid regurgitation presenting following&#xD;
             conditions:&#xD;
&#xD;
               1. TR severity of at least 3 (severe) on a scale of 0 (none) to 5 (torrential),&#xD;
                  assessed by independent core lab and/or&#xD;
&#xD;
               2. symptoms requiring use of diuretics.&#xD;
&#xD;
          -  Subject presenting with New York Heart Association Class NYHA ≥II.&#xD;
&#xD;
          -  Subject is not eligible for open tricuspid valve surgery due to high operative risk,&#xD;
             as determined by a Heart Team decision.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject in need of emergent or urgent intervention or any planned cardiac intervention&#xD;
             within the next 12 months.&#xD;
&#xD;
          -  Subject undergoing cardiac interventions within 30 days prior to index procedure.&#xD;
&#xD;
          -  Subject with concomitant clinically relevant mitral, aortic, pulmonary&#xD;
             regurgitation/stenosis.&#xD;
&#xD;
          -  Subject who had previous tricuspid valve replacement or repair and a device is still&#xD;
             in situ.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabien Praz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inselspital, Universitätsspital Bern, Universitätsklinik für Kardiologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Esther Gerteis</last_name>
    <phone>+41796015318</phone>
    <email>gerteis@tricares.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inselspital, Universitätsspital Bern, Universitätsklinik für Kardiologie</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabien Praz, MD</last_name>
      <email>Fabien.praz@insel.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 28, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

